The synthetic bone-graft materials developed by this Hertfordshire company are used in a range of orthopaedic applications, including spinal fusion and trauma repair. The success of its products Actifuse and Apapore secured £23m in private equity from 3i and the New York hedge fund HealthCor in June 2008. This enabled the company to almost treble its staff, quadruple manufacturing capacity, and develop new products including a next-generation ceramic material that stimulates bones to grow more rapidly. Apatech was founded in 2001 and is led by chief executive Simon Cartmell. Its sales have grown 180% a year from £1m in 2006 to £22.8m in 2009.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.